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Abstract. Non-small cell lung cancer (NSCLC) is one of the 
most common malignant tumours in the Western world and 
is associated with a poor prognosis. Biomarkers predicting 
prognosis and therapeutic effects are highly required, and 
cell-free DNA (cfDNA) may be a feasible option. Genetic 
mutations can be analysed in plasma and may increase the 
scientific use of such measurements. In the present study, we 
investigated: i) the dynamics of cfDNA and plasma mutated 
KRAS (pmKRAS) during the treatment of patients with 
advanced NSCLC; and ii) the prognostic value of baseline 
cfDNA and pmKRAS. Sixty-nine patients were included 
in a prospective biomarker trial. Inclusion criteria included 
advanced NSCLC, candidate for first-line treatment, no 
previous cancer within the five years prior to this study. Blood 
samples were drawn at baseline, day 8 and at progression. 
Analyses of cfDNA and KRAS mutations in plasma were 
performed using an in-house qPCR assay. Evaluation of 
the treatment effect and status at follow-up was performed 
according to RECIST 1.1. The median levels of cfDNA were 
significantly higher at progression (9,250 alleles/ml) than at 
baseline (5,450 alleles/ml). Overall survival and progression-
free survival were both significantly shorter in patients with 
high levels of cfDNA (above the 75th percentile) compared to 
lower levels. Only few patients harboured KRAS mutations 
in plasma. Two patients had no KRAS mutations in plasma 
at baseline, but mutations appeared in the subsequent blood 
samples. High baseline levels of cfDNA indicate a poor prog-
nosis. The level changes during the treatment course with 
a significant increase at progression, suggesting a possible 
predictive value of cfDNA. The plasma KRAS status may 
change during treatment with potential implications for treat-
ment selection.
Introduction
Lung cancer is one of the most common malignancies in 
the Western world and also in Denmark (1,2). It is highly 
associated with smoking and, despite significant efforts in 
antismoking campaigns, the incidence is still increasing. Lung 
cancer can be sub-classified into small cell lung cancer (SCLC) 
and non-small cell lung cancer (NSCLC), with NSCLC being 
the most common (80%). NSCLC can be further classified 
according to histology and genetic composition. The treatment 
of NSCLC comprises surgery, radiotherapy, chemotherapy 
and/or biological treatment, depending on the stage of disease, 
co-morbidity and the patient's general health. The disease may 
be cured by surgery, but the majority of patients are diagnosed 
at an advanced stage, leaving palliative treatment as the 
only option. Thus, the prognosis is often poor with only few 
patients experiencing long-term survival, calling for treatment 
improvements.
New treatment strategies are rapidly emerging and most 
are biological compounds with specific targets such as the 
epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR TKIs), which have proven highly effective in patients 
with activating EGFR mutations. Another treatment strategy 
are the EML4-ALK inhibitors effective in EML4-ALK posi-
tive lung cancer (3-6). Common characteristics for these genetic 
changes are that they are more frequent in adenocarcinomas 
and represent an early event in the development of cancer. 
Furthermore, it has become evident that new mutations may 
appear during the course of the disease, and the initial biopsy 
may, therefore, be insufficient as the basis for choice of treat-
ment (7). Some of the mutations arising confer resistance to the 
current treatment (such as the EGFR T790M mutation causing 
resistance to EGFR TKIs) and identification of such mutations 
at an early stage may help tailor the treatment (7,8). With the 
increasing knowledge of the complex genetic composition of 
NSCLC, mutation testing at baseline has gained significance.
To date, mutation analyses are generally performed on 
DNA derived from tumour tissue and, for practical reasons, 
mostly from the initial diagnostic biopsy. The new insights 
into the mutation status possibly changing throughout the 
treatment course necessitate repeated mutation analyses, 
leaving the clinicians with the dilemma of either performing 
multiple invasive procedures or staying on the path pointed out 
by the initial biopsy. Recent years have seen new and refined 
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methods of identifying mutations in DNA derived from a 
blood sample, offering a highly appealing way of reducing the 
need for sequential invasive procedures.
The plasma mutated DNA represents a fraction of the 
cell-free DNA (cfDNA), which is small fragments of DNA 
circulating in the blood stream. The biological mechanisms 
underlying cfDNA remain to be fully understood, but 
increased apoptosis, necrosis of tumour cells, active release 
and lysis of circulating tumour cells (CTCs) have been 
proposed (9). cfDNA is present in both healthy individuals and 
patients with non-cancerous diseases, but the levels increase 
in patients with malignant diseases, probably due to increased 
activity of the aforementioned processes. Several studies have 
demonstrated a prognostic value of the total level of cfDNA, 
with high levels being associated with shorter survival (10-15). 
Furthermore, the qualitative perspective in terms of tumour-
specific mutations has been investigated, demonstrating that it 
is indeed possible to identify tumour-specific mutations in the 
blood to serve as prognostic or predictive markers in different 
treatment settings (16,17). The possibility of monitoring the 
disease opens new options calling for further investigation. 
Quantitative changes during the treatment course may predict 
the effect of the treatment and, thus, may represent a new tool 
for treatment monitoring, while qualitative changes such as 
new mutations in plasma are another important aspect (17,18).
The present study investigated the relationship between the 
level of cfDNA and the disease development at different time-
points during the course of disease. Furthermore, the plasma 
KRAS mutation status during treatment and the prognostic 
impact of cfDNA was analysed.
Materials and methods
Patients. Patients with newly diagnosed, histopathologically 
confirmed stage III-IV NSCLC were included in a prospec-
tive biomarker study at the Department of Oncology, Vejle 
Hospital. Patients were included based on the following 
criteria: candidate for first-line treatment, age >18 years, no 
previous cancer diagnosis within five years before their inclu-
sion in this study and written informed consent. The treatment 
comprised carboplatin [(GFR+25) x AUC mg i.v. on day 1] 
and vinorelbine (30 mg/m2 i.v. on day 1 and 60 mg/m2 p.o. on 
day 8), alone or with bevacizumab (7.5 mg/m2 i.v. on day 1).
Blood samples for analysis of cfDNA were drawn at base-
line (within two weeks before treatment start), on day 8 of the 
first treatment cycle and at time of progression. The samples 
were stored at -80˚C until further analyses.
All patients had a baseline CT of the chest and upper 
abdomen within a month prior to treatment start. The treat-
ment effect was evaluated by CT scans of the chest and upper 
abdomen and repeated at follow-up. Objective response rate 
was determined according to RECIST v.1.1 (19). The primary 
end-points were overall survival (OS) and progression-free 
survival (PFS).
The study was approved by the Regional Scientific Ethics 
Committee for Southern Denmark in accordance with the 
Danish law. 
Plasma analyses of cfDNA and KRAS. A peripheral blood 
sample of 20 ml collected in EDTA-tubes was drawn at each 
time-point and plasma was subsequently isolated by centrifuga-
tion at 2,000 x g for 10 min. The plasma was separated within 
2 h of blood sampling and subsequently stored at -80˚C until 
further analysis. Total nucleic acid was extracted from 1.0 ml 
plasma by the use of a QIAsymphony virus/bacteria midi-kit on 
a QIAsymphony robot (Qiagen) according to the manufacturer's 
instructions. Both cfDNA and KRAS mutations were analysed 
by qPCR and an in-house developed assay. To determine the 
level of cfDNA a one-genome equivalent gene, the β2 micro-
globuline (B2M) was used. The B2M-gene is not involved in 
carcinogenesis but is present in all cells and is therefore suit-
able for determining the total level of cfDNA regardless of 
cellular origin. The sequence of the forward primer was 3'-TAA 
AACTTAATGTCTTCCTTTTTTTTCTC-5', the reverse 
primer was 3'-AAACATTTTCTCAAGGTCAAAAACTTA-5', 
and the probe Fam-CCTCCATGATGCTGCTTACATGTC 
TC-Tamra. The rather small PCR product (102 bp) increases 
the sensitivity of the analysis, since smaller cfDNA fragments 
are more likely to be detected.
In order to prevent overestimation of the cfDNA caused by 
lysis of leukocytes or accidental mixing of leukocytes into the 
plasma, the samples were analysed for leukocyte contamina-
tion. Samples with evidence of leukocytes were excluded from 
the quantitative analyses.
The KRAS mutations were also analysed by in-house 
qPCR assays as previously described in detail (14,20). In brief, 
six mutations of codon 12 and one in codon 13 of the KRAS-
gene were identified by an ARMS-qPCR method. The high 
specificity of the method allowed for identification of KRAS 
mutations despite high background DNA.
All the reactions were run as doublets and the qPCR results 
were demonstrated as an amplification plot and subsequently 
transformed into alleles/ml as previously described (14).
Statistical analysis. The correlations between patient char-
acteristics, cfDNA and pmKRAS were investigated by 
non-parametric Wilcoxon rank sum test, χ2 test or Fischer's 
exact test when appropriate. The same tests were used for 
correlations between objective response rate and cfDNA level. 
Differences in level of cfDNA between different time-points 
of blood sampling were investigated by Wilcoxon rank-sum 
test. Survival analyses were evaluated by Kaplan-Meier plots 
and any differences between the groups were estimated by the 
log-rank method.
PFS was calculated as time between first day of treatment 
and objective progression or mortality due to any cause. OS 
was calculated as time between first day of treatment and date 
of mortality due to any cause. Patients with no events were 
censored by the last date of observation (May 15, 2013).
All statistical analyses were carried out in NSCSS statis-
tical software (version 07.1.15 2009; NCSS Statistical Software, 
Kaysville, UT, USA). Two-sided P-value <0.05 was considered 
to indicate a statistically significant result.
Results
Patient selection. The present study included 69 patients. 
Patients with leukocyte contamination were excluded leaving 
58 patients for analysis of cfDNA. The patient selection process 
is demonstrated in the consort diagram (Fig. 1) and patient 
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characteristics are provided in Table I. The patient characteris-
tics were correlated with the baseline level of cfDNA. Patients 
with distant metastases (median cfDNA 7,100 alleles/ml) had 
a significantly higher level of cfDNA compared to patients 
without metastases (median cfDNA 4,900 alleles/ml; P=0.04). 
Furthermore, the patient characteristics were tested for differ-
ences in PFS and OS, but no significant differences were found 
in any of the variables. 
Dynamics of cfDNA during treatment. When comparing the 
median level of cfDNA at baseline and time of progression 
(n=26), there was a significantly higher median at progression 
(9,250 alleles/ml) compared to baseline (5,450 alleles/ml); 
P=0.02). There were no significant differences between the 
level at baseline and on day 8 but a significantly higher level at 
progression compared to day 8 (data not shown).
Response was evaluated according to RECIST v.1.1, and 
the best overall response was correlated with the change in 
total cfDNA from baseline to day 8. There was no obvious 
trend in the change of cfDNA depending on response. Due 
to the large differences in the level of cfDNA between the 
patients, the response was correlated with the size of change 
in terms of percent. There was no significant difference in 
response (PR, vs. NC vs. PD) between patients with an increase 
or decrease in cfDNA larger than either 25 or 50%. There were 
no significant differences when the patients were grouped into 
stable disease (PR+NC) vs. PD either.
Fig. 2 illustrates the levels of cfDNA during the therapy in 
the 20 individual patients with cfDNA analyses available at 
all three time-points. Seventeen patients (85%) had increasing 
values at progression. The difference between baseline 
(median cfDNA, 5,320 alleles/ml) and progression (median 
cfDNA, 9,250 alleles/ml) was significant (P=0.01).
Dynamics of pmKRAS during treatment. Only seven of the 
patients were identified with a plasma KRAS mutation at 
baseline (10%). The mutation persisted during the treatment 
course. Two patients had changing mutation status during the 
Figure 1. Consort diagram of the patient selection procedure. *Analyses of correlation between baseline cfDNA and prognosis (OS and PFS). †Leukocyte 
contamination at progression or baseline. ‡Leukocyte contamination on day 8 or at baseline. Some patients did not progress before the end of the study period 
and were excluded and designated as the group of patients with ‘no blood sample at PD’.
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treatment period. The first patient had no mutation at either 
baseline or day 8, but at progression, and the second patient 
had no mutation at baseline but at day 8 and at progression. 
Prognostic value of cfDNA. When investigating the prognostic 
value, the initial cut-off was set at quartiles, as previously 
described (12). By this exploratory approach, a significant 
difference between patients in the lower three quartiles and the 
upper fourth was observed (P<0.05; data not shown), leading 
to further dichotomisation by the upper fourth quartile. 
This revealed a significantly shorter median OS of patients 
with high levels of cfDNA. The median survival time of 
all patients was 8.0 months (95% CI, 6.7-9.3). Patients with 
high levels of cfDNA had a significantly shorter OS (median, 
4.6 months; 95% CI, 2.7-5.6) than patients with lower levels 
(median, 8.7 months; 95% CI 7.9-11.4; HR, 3.1, 95% CI 1.2-8.0; 
P=0.0004). Nineteen patients were censored. Survival curves 
are demonstrated in Fig. 3.
In addition to OS, PFS according to the baseline level of 
cfDNA was also investigated. As shown in Fig. 3, there were 
significant differences in PFS in patients with high vs. low 
levels of cfDNA. Eight patients were censored. The median 
PFS of patients with cfDNA >75% was 2.6 months (95% CI, 
1.4-4.6) compared to 5.8 months (95% CI, 4.3-6.8) of the other 
patients (HR, 2.0; 95% CI, 1.0-4.3; P=0.03).
cfDNA at day 8 (n=56) was not correlated with either PFS 
or OS (P>0.05; data not shown).
Prognostic value of plasma mutated KRAS (pmKRAS). 
pmKRAS was identified and quantified. Only 7/69 patients 
(10%) had a mutation at baseline and further statistical anal-
yses of the quantitative impact of pmKRAS were therefore 
not possible. Qualitative analyses were performed with the 
patients divided into two groups, with mutations or wild-type 
(WT). Nine patients were censored for PFS and 22 for OS. The 
median OS in the mutated group was significantly shorter than 
Table I. Patient characteristics.
Characteristics Baseline values
No. of patients, n (%) 58 (100)
Age (years)
  Median (range) 64 (46-84)
Gender, n (%)
  Male  33 (57)
  Female 25 (43)
Histology, n (%)
  Adenocarcinoma 48 (83)
  SCCa 8 (14)
  Unclassified 2 (3)
Stage, n (%)
  III 6 (10)
  IV 52 (90)
Distant metastasesb, n (%)
  Yes 44 (76)
  No 14 (24)
CNS metastases, n (%)
  Yes 8 (14)
  No 50 (86)
ECOG PSc at baseline, n (%)
  0 21 (36)
  1 29 (50)
  2 8 (14)
LDH at baseline, n (%)
  Normal 33 (57)
  Elevated 22 (38)
  Missing 3 (5)
Treatment regimen, n (%)
  Carboplatin + vinorelbine (CN)d 36 (62)
  CN + bevacizumab 22 (38)
aSCC; squamous cell carcinoma; bCentral nervous system (CNS) 
metastases not included; cECOG PS; Eastern Cooperative Oncology 
Group Performance Status; done of the patients received vinorelbine 
as monotherapy.
Figure 2. Box plot and ratio plot of the cfDNA level at different time-points.
(A) The box plot illustrates the levels of cfDNA at baseline, day 8 and pro-
gression, and the P-values at the different time-points (Wilcoxon rank-sum 
test). (B) The ratio plot illustrates the changes in cfDNA from baseline to 
day 8 and at progression. Each line represents one patient (n=20).
  A
  B
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in the WT group [median 3.6 (95% CI, 2.1-4.3) vs. 8.4 months 
(95% CI, 7.3-10.0; HR; 2.5 (95% CI, 0.7-8.6); P=0.03]. The 
same was observed in PFS, where patients harbouring a 
mutation had a median PFS of 2.1 months (95% CI, 1.3-2.1) 
compared to 5.5 months (95% CI, 4.6-6.0) in the WT patients 
[HR, 2.6 (95% CI, 0.8-8.6); P=0.01]. Survival curves are 
shown in Fig. 4.
Discussion
The focus on and the need for sequential genetic testing 
throughout the course of the disease is rapidly increasing. 
Patient-friendly methods rather than invasive procedures are 
highly warranted, and the possibility of identifying reliable 
biomarkers and even tumour-specific mutations in a blood 
sample is highly advantageous. In the present study, we inves-
tigated both the level of cfDNA and the tumour-specific KRAS 
mutation in plasma at three different time-points. The material 
was prospectively collected by enrolment in a pre-defined 
biomarker protocol making the patient group homogenous 
and, importantly, also comparable with previous studies of the 
same area (12,16).
The analyses were performed by an in-house developed 
assay, which has been used, validated and previously described 
in detail (14,16,20). The PCR-fragment used in the present 
study was short (only 102 bp), increasing the detection rate 
of even small fragments of cfDNA in the plasma. A method 
for identifying samples with possible leukocyte contamination 
was also used, enabling exclusion of patients with an unreli-
able estimation of the level of cfDNA. 
The level of cfDNA changed significantly from base-
line to progression, but not between baseline and day 8, 
indicating a correlation between disease progression and 
increasing levels of cfDNA. Day 8 may be too early to 
detect any significant indications of the prognosis, but the 
same measurement at later time-points may be of interest 
in order to predict progression at an early stage. The issue 
has been investigated by other authors, although only few 
studies are available. In 2001, Sozzi et al (21) investigated the 
level of cfDNA before and after surgery and at follow-up of 
38 patients with NSCLC. A reduction of cfDNA was seen in 
the relapse-free patients, while four patients had increasing 
levels in following measurements of cfDNA. Notably, all 
patients with increasing levels subsequently presented with 
cancer.
In agreement with our data, Kumar et al (22) also reported 
increasing levels of cfDNA in patients with progression after 
three courses of chemotherapy in 42 patients with advanced 
Figure 3. PFS and OS according to baseline level of cfDNA. (A) PFS (n=58). 
Median PFS <75%, 5.8 months (4.3-6.8); median PFS >75%, 2.6 months 
(1.4-4.6). HR, 2.0 (95% CI 1.0-4.3); P=0.03. (B) OS (n=58). Median OS 
<75%, 8.7 months (7.9-11.4); median OS >75%, 4.6 months (2.7-5.6). HR, 3.1 
(95% CI 1.2-8.0); P=0.0004. The solid line represents patients with cfDNA 
in the >75th percentile and the dotted line patients with cfDNA in the <75th 
percentile.
Figure 4. PFS and OS according to pmKRAS status [mutated or wild-type 
(WT)] at baseline (n=69). (A) PFS in all patients (n=69). Median PFS pmKRAS 
WT, 5.5 months (4.6-6.0); median PFS pmKRAS mutated, 2.1 months (1.3-2.1). 
HR, 2.6 (95% CI, 0.8-8.6); P=0.01. (B) OS in all patients (n=69). Median 
OS pmKRAS WT, 8.4 months (7.3-10.0); median OS pmKRAS mutated, 
3.6 months (2.1-4.3). HR, 2.5 (95% CI, 0.7-8.6); P=0.03. The solid line repre-
sents patients with a KRAS mutation (n=7), the dotted line WT patients  (n=62).
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NSCLC. However, in contrast to our observations, the authors 
were not able to demonstrate any prognostic value of the 
baseline level of cfDNA as in the present study. Reasons for 
these discrepancies may be different cut-off limits as well as a 
heterogeneous patient population.
We examined the dynamics of pmKRAS at the different 
time-points. Ten percent of the patients had a KRAS mutation 
at baseline, which is lower than expected, but may be due to 
the relatively low number of patients included or, undetectable, 
low levels of KRAS in the circulation. Of note, two patients 
without detectable KRAS mutation at baseline were subse-
quently identified with KRAS mutations in the plasma. One of 
the patients had a mutation both on day 8 and at progression, 
while the other had a mutation only at time of progres-
sion. The findings may reflect limitations of the method in 
detecting KRAS mutations in plasma, tumour heterogeneity 
with increasing levels of the KRAS-mutated clone during 
treatment, or the appearance of new mutations. The same 
phenomenon has previously been demonstrated in metastatic 
colorectal cancer and is also discussed in a review by Mok (7), 
suggesting that new mutations may arise as a consequence of 
selection pressure during treatment (14).
In addition to the dynamics of cfDNA and pmKRAS, we 
investigated the prognostic value of the two parameters at 
baseline. We previously demonstrated an independent prog-
nostic value of the level of cfDNA and the mutational status 
of pmKRAS in similar patient material and sought to validate 
these findings (12,16). The same cut-off limits based on quar-
tiles and subsequent dichotomisation at the 75th percentile 
were used in the present study. We were able to validate the 
prognostic value of cfDNA both at the level of quartiles and at 
the 75th percentile, with higher levels of cfDNA being associ-
ated with a shorter OS and PFS. Furthermore, in our previous 
study, a subgroup analysis of patients with both high levels of 
cfDNA (>75th percentile) and a poor PS (PS=2) showed an 
even poorer prognosis for these patients. In the present study, 
only two patients fulfilled these criteria, leaving no room for 
further statistical analyses.
Our previous study showed an independent prognostic 
value of the presence of KRAS mutations in plasma, the muta-
tions being associated with a poorer prognosis (16). Despite 
the low number of patients with pmKRAS in the present study, 
the results of our previous study were confirmed, indicating a 
prognostic value of pmKRAS in this setting.
cfDNA is a potentially valuable tool in monitoring treat-
ment effect in patients with NSCLC, but the optimal time for 
analysis remains to be defined. Furthermore, tumour-specific 
mutations such as KRAS appear to be a dynamic phenomenon 
highlighting the need for repeated analyses of the tumour's 
genetic composition. The present results confirmed our 
previous findings, but further studies are required to outline 
the field of optimal clinical application of cfDNA and tumour-
specific mutations measured in plasma.
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